Pancreatic cancer-induced cachexia is Jak2-dependent in mice

Journal of Cellular Physiology

Volumn 229, Issue 10, 2014, Pages 1437-1443

  Gilabert, Marine ^a   Calvo, Ezequiel ^b   Airoldi, Ana ^a   Hamidi, Tewfik ^a   Moutardier, Vincent ^a,c   Turrini, Olivier ^a,d   Iovanna, Juan ^a  

^a AIX MARSEILLE UNIVERSITY   (France)

^b LAVAL UNIVERSITY   (Canada)

^c HÔPITAL NORD   (France)

^d INSTITUT PAOLI CALMETTES   (France)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 1; INTERLEUKIN 22; INTERLEUKIN 4; INTERLEUKIN 6; JANUS KINASE 2; N BENZYL 2 CYANO 3 (3,4 DIHYDROXYPHENYL)ACRYLAMIDE; STAT3 PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BODY WEIGHT; CACHEXIA; CANCER CHEMOTHERAPY; CANCER GROWTH; CONTROLLED STUDY; DRUG EFFECT; ENZYME ACTIVATION; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; GENE EXPRESSION; INTRACELLULAR SIGNALING; MICROARRAY ANALYSIS; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PANCREAS CANCER; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SIGNAL TRANSDUCTION; WHITE ADIPOSE TISSUE;

ADENOCARCINOMA; ADIPOSE TISSUE, WHITE; ANIMALS; BODY WEIGHT; CACHEXIA; GENE EXPRESSION PROFILING; INTERLEUKIN-6; JANUS KINASE 2; LIVER; MICE; MICE, TRANSGENIC; MUSCLE, SKELETAL; PANCREATIC NEOPLASMS; PHOSPHORYLATION; PROTEIN KINASE INHIBITORS; SIGNAL TRANSDUCTION; STAT3 TRANSCRIPTION FACTOR; TIME FACTORS; TYRPHOSTINS;

EID: 84903462699     PISSN: 00219541     EISSN: 10974652     Source Type: Journal    
DOI: 10.1002/jcp.24580     Document Type: Article

References (36)

1. Aguirre AJ, Bardeesy N, Sinha M, Lopez L, Tuveson DA, Horner J, Redston MS, DePinho RA. 2003. Activated Kras and Ink4a/Arf deficiency cooperate to produce metastatic pancreatic ductal adenocarcinoma. Genes Dev 17:3112-3126.
2. Ando K, Takahashi F, Motojima S, Nakashima K, Kaneko N, Hoshi K, Takahashi K. 2013. Possible role for tocilizumab, an anti-interleukin-6 receptor antibody, in treating cancer cachexia. J Clin Oncol 31:e69-e72.
3. Bachmann J, Heiligensetzer M, Krakowski-Roosen H, Buchler MW, Friess H, Martignoni ME. 2008. Cachexia worsens prognosis in patients with resectable pancreatic cancer. J Gastrointest Surg 12:1193-1201.
4. Bardeesy N, Aguirre AJ, Chu GC, Cheng KH, Lopez LV, Hezel AF, Feng B, Brennan C, Weissleder R, Mahmood U, Hanahan D, Redston MS, Chin L, Depinho RA. 2006. Both p16(Ink4a) and the p19(Arf)-p53 pathway constrain progression of pancreatic adenocarcinoma in the mouse. Proce Natl Acad Sci USA 103:5947-5952.
5. Baud V, Karin M. 2001. Signal transduction by tumor necrosis factor and its relatives. Trends Cell Biol 11:372-377.
6. Baumgarten AJ, Fiebig HH, Burger AM. 2007. Molecular analysis of xenograft models of human cancer cachexia-Possibilities for therapeutic intervention. Cancer Genomics Proteomics 4:223-231.
7. Bayliss TJ, Smith JT, Schuster M, Dragnev KH, Rigas JR. 2011. A humanized anti-IL-6 antibody (ALD518) in non-small cell lung cancer. Expert Opin Biol Ther 11:1663-1668.
8. Benjamini Y, Drai D, Elmer G, Kafkafi N, Golani I. 2001. Controlling the false discovery rate in behavior genetics research. Behav Brain Res 125:279-284.
9. Bonetto A, Aydogdu T, Kunzevitzky N, Guttridge DC, Khuri S, Koniaris LG, Zimmers TA. 2011. STAT3 activation in skeletal muscle links muscle wasting and the acute phase response in cancer cachexia. PloS ONE 6:e22538.
10. Bonetto A, Aydogdu T, Jin X, Zhang Z, Zhan R, Puzis L, Koniaris LG, Zimmers TA. 2012. JAK/STAT3 pathway inhibition blocks skeletal muscle wasting downstream of IL-6 and in experimental cancer cachexia. Am J Physiol Endocrinol Metab 303:E410-421.
11. Buck M, Zhang L, Halasz NA, Hunter T, Chojkier M. 2001. Nuclear export of phosphorylated C/EBPbeta mediates the inhibition of albumin expression by TNF-alpha. EMBO J 20:6712-6723.
12. Calvano SE, Xiao W, Richards DR, Felciano RM, Baker HV, Cho RJ, Chen RO, Brownstein BH, Cobb JP, Tschoeke SK, Miller-Graziano C, Moldawer LL, Mindrinos MN, Davis RW, Tompkins RG, Lowry SF. 2005. Inflamm, Host Response to Injury Large Scale Collab. Res P. A network-based analysis of systemic inflammation in humans. Nature 437:1032-1037.
13. Cano CE, Sandi MJ, Hamidi T, Calvo EL, Turrini O, Bartholin L, Loncle C, Secq V, Garcia S, Lomberk G, Kroemer G, Urrutia R, Iovanna JL. 2012. Homotypic cell cannibalism, a cell-death process regulated by the nuclear protein 1, opposes to metastasis in pancreatic cancer. EMBO Mol Med 4:964-979.
14. Chirgwin JM, Przybyla AE, MacDonald RJ, Rutter WJ. 1979. Isolation of biologically active ribonucleic acid from sources enriched in ribonuclease. Biochemistry 18:5294-5299.
15. Costelli P, Carbo N, Tessitore L, Bagby GJ, Lopez-Soriano FJ, Argiles JM, Baccino FM. 1993. Tumor necrosis factor-alpha mediates changes in tissue protein turnover in a rat cancer cachexia model. J Clin Investig 92:2783-2789.
16. Dymock BW, See CS. 2013. Inhibitors of JAK2 and JAK3: An update on the patent literature 2010-2012. 23:pp 449-501.
17. Fearon KC, McMillan DC, Preston T, Winstanley FP, Cruickshank AM, Shenkin A. 1991. Elevated circulating interleukin-6 is associated with an acute-phase response but reduced fixed hepatic protein synthesis in patients with cancer. Ann Surg 213:26-31.
18. Fearon K, Strasser F, Anker SD, Bosaeus I, Bruera E, Fainsinger RL, Jatoi A, Loprinzi C, MacDonald N, Mantovani G, Davis M, Muscaritoli M, Ottery F, Radbruch L, Ravasco P, Walsh D, Wilcock A, Kaasa S, Baracos VE. 2011. Definition and classification of cancer cachexia: An international consensus. Lancet Oncol 12:489-495.
19. Fearon KC, Glass DJ, Guttridge DC. 2012. Cancer cachexia: Mediators, signaling, and metabolic pathways. Cell Metab 16:153-166.
20. Gordon JN, Trebble TM, Ellis RD, Duncan HD, Johns T, Goggin PM. 2005. Thalidomide in the treatment of cancer cachexia: A randomised placebo controlled trial. Gut 54:540-545.
21. Gu G, Dubauskaite J, Melton DA. 2002. Direct evidence for the pancreatic lineage: NGN3+ cells are islet progenitors and are distinct from duct progenitors. Development 129:2447-2457.
22. Hebenstreit D, Horejs-Hoeck J, Duschl A. 2005. JAK/STAT-dependent gene regulation by cytokines. Drug News Perspect 18:243-249.
23. Irizarry RA, Hobbs B, Collin F, Beazer-Barclay YD, Antonellis KJ, Scherf U, Speed TP. 2003. Exploration, normalization, and summaries of high density oligonucleotide array probe level data. Biostatistics 4:249-264.
24. Johns N, Stephens NA, Fearon KC. 2013. Muscle wasting in cancer. Int J Biochem Cell Biol 45:2215-2229.
25. Langstein HN, Doherty GM, Fraker DL, Buresh CM, Norton JA. 1991. The roles of gamma-interferon and tumor necrosis factor alpha in an experimental rat model of cancer cachexia. Cancer Res 51:2302-2306.
26. Mantovani G, Maccio A, Massa E, Madeddu C. 2001. Managing cancer-related anorexia/cachexia. Drugs 61:499-514.
27. Meydan N, Grunberger T, Dadi H, Shahar M, Arpaia E, Lapidot Z, Leeder JS, Freedman M, Cohen A, Gazit A, Levitzki A, Roifman CM. 1996. Inhibition of acute lymphoblastic leukaemia by a Jak-2 inhibitor. Nature 379:645-648.
28. Schwarzkopf M, Coletti D, Sassoon D, Marazzi G. 2006. Muscle cachexia is regulated by a p53-PW1/Peg3-dependent pathway. Genes Dev 20:3440-3452.
29. Smyth GK. 2004. Linear models and empirical bayes methods for assessing differential expression in microarray experiments. Stat Appl Genet Mol Biol 3:Article 3.
30. Strassmann G, Fong M, Kenney JS, Jacob CO. 1992. Evidence for the involvement of interleukin 6 in experimental cancer cachexia. J Clin Investig 89:1681-1684.
31. Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA, Paulovich A, Pomeroy SL, Golub TR, Lander ES, Mesirov JP. 2005. Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci USA 102:15545-15550.
32. Tisdale MJ. 1998. New cachexic factors. Curr Opin Clin Nutr Metab Care 1:253-256.
33. Tisdale MJ. 2002. Cachexia in cancer patients. Nat Rev Cancer 2:862-871.
34. Verstovsek S, Kantarjian H, Mesa RA, Pardanani AD, Cortes-Franco J, Thomas DA, Estrov Z, Fridman JS, Bradley EC, Erickson-Viitanen S, Vaddi K, Levy R, Tefferi A. 2010. Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis. N Engl J Med 363:1117-1127.
35. Watchorn TM, Dowidar N, Dejong CH, Waddell ID, Garden OJ, Ross JA. 2005. The cachectic mediator proteolysis inducing factor activates NF-kappaB and STAT3 in human Kupffer cells and monocytes. Int J Oncol 27:1105-1111.
36. Zhang L, Pan J, Dong Y, Tweardy DJ, Dong Y, Garibotto G, Mitch WE. 2013. Stat3 activation links a C/EBPdelta to myostatin pathway to stimulate loss of muscle mass. Cell Metab 18:368-379.